Clinical Studies 14.1 Glycemic Control in Adults with Type 2 Diabetes Mellitus Overview of Clinical Trials of FARXIGA in Adults with Type 2 Diabetes Mellitus FARXIGA has been studied in adult patients as monotherapy, in combination with metformin, pioglitazone, sulfonylurea (glimepiride), sitagliptin (with or without metformin), metformin plus a sulfonylurea, or insulin (with or without other oral antidiabetic therapy), compared to a sulfonylurea (glipizide), and in combination with a GLP-1 receptor agonist (exenatide extended release) added on to metformin
The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function
There are some interesting animal studies that show that it could have some positive benefits, but there are also reasons to be really concerned about it
Zepbound was approved by the FDA in late 2023 for chronic weight management in adults with obesity or overweight who also have weight-related health problems
You should contact your GP or healthcare provider if you experience: Persistent vomiting lasting more than 2448 hours, or vomiting that prevents you from keeping down fluids or medications Signs of dehydration , including dark urine, dizziness when standing, dry mouth, reduced urination, or confusion Severe abdominal pain , particularly if constant or accompanied by fever, as this may indicate pancreatitis (a rare but serious side effect) Vomiting blood or material that looks like coffee grounds Inability to tolerate any food or fluids for more than 24 hours Symptoms of hypoglycaemia (low blood sugar) if you also take insulin or sulphonylureas, including trembling, sweating, confusion, or rapid heartbeat Seek emergency care (call 999 or go to A&E) if you have severe abdominal pain, are vomiting blood, have signs of severe dehydration, or are experiencing symptoms of pancreatitis
That is the entire body of published clinical work for BPC-157
